<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingJeffrey A. Engelman, Pasi A. Jänne, Takayuki Kosaka et al.|Science|2007Cited by 4.5k
Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckLori J. Wirth, Marshall R. Posner, Robert I. Haddad et al.|Journal of Clinical Oncology|2005Cited by 104
A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencingTorstein Tengs, Roman K. Thomas, Jeff C. Lee et al.|Cancer Letters|2005Cited by 38
A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. scoreZongxin Chen, Chen Huang, Jun Zhang et al.|BMC Cancer|2023Cited by 9
New model of PIRADS and adjusted prostate-specific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic studyChen Huang, Yuhua Huang, Zongqiang Cai et al.|Asian Journal of Andrology|2022Cited by 6